Published Date: 18 Mar 2024
For CLL/SLL patients who are refractory or have relapsed, lixocabtagene maraleucel (Breyanzi) has a new indication.
Read Full News1.
Study: For predicting breast cancer, AI performs better than traditional risk models.
2.
Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.
3.
Targeted radiation therapy shows near-complete response in rare sarcoma patients
4.
Chicken Broth Recall; Medicaid at Risk; Princess Kate Thanks Medical Staff
5.
Clinical trial could lead to new 'gold standard' test for prostate cancer detection
1.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
2.
The Truth About Marijuana and Its Effect on Mental Health
3.
Hope in Numbers: Understanding AML Leukemia Survival Rates and Emerging Therapies
4.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
5.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
Oropharyngeal Cancer in Relation to HPV Status
4.
Navigating the Complexities of Ph Negative ALL - Part I
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation